Research Article| Volume 19, ISSUE 3, P459-470, May 1997

Efficacy and tolerability of doxazosin versus enalapril in the treatment of patients with mild-to-moderate hypertension

      This paper is only available as a PDF. To read, Please Download here.


      The effects of 4 weeks of treatment with doxazosin or enalapril on diastolic blood pressure (DBP) and plasma lipid levels were studied in 160 patients 18 to 50 years old with mild-to-moderate hypertension. Comparing baseline measurements with measurements taken after 4 weeks, DBP was significantly reduced by 6.8 ± 7.4 (mean ± SD) mm Hg and 12.0 ± 7.1 mm Hg in the doxazosin and enalapril groups, respectively. Systolic blood pressure was significantly decreased from baseline to end of treatment in both groups. There were no significant changes in heart rate from baseline to end of treatment in the doxazosin group, but there was a statistically significant decrease in heart rate in the enalapril group. High-density lipoprotein cholesterol increased statistically significant in the doxazosin group but not in the enalapril group. A decrease in triglycerides was statistically significantly with respect to the doxazosin group and was close to significance for the enalapril group. Forty-nine (62%) patients in the doxazosin group and 43 (54%) patients in the enalapril group reported at least one adverse event. Significant reductions in DBP after 4 weeks of treatment were achieved by both drugs, each taken once daily. This reduction was more pronounced in the enalapril group 24 hours postdose, with a mean final daily dose of 2.8 mg of doxazosin and 12.6 mg of enalapril. However, even relatively short-term treatment with low-dose doxazosin showed a more favorable effect on lipids than did enalapril.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Neaton JD
        • Grimm RH
        • Prineas RJ
        • et al.
        Treatment of mild hypertension study.
        JAMA. 1993; 270 (Final results): 713-724
        • Taylor SH
        • Lee PS
        • Sharma SK
        A comparison of doxazosin and enalapril in the treatment of mild and moderate essential hypertension.
        Am Heart J. 1986; 116: 1820-1825
        • Wessels F
        Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension.
        Am Heart J. 1991; 121: 299-303
        • Hayduk K
        • Schneider HT
        Antihypertensive effects of doxazosin in systemic hypertension and comparison with terazosin.
        Am J Cardiol. 1987; 59: 95G-98G
        • Smyth P
        • Pringle S
        • Jackson G
        • Lorimer AR
        24-Hour control of blood pressure by once daily doxazosin: A multicentre double-blind comparison with placebo.
        Eur J Clin Pharmacol. 1988; 34: 613-618
        • Rosenthal J
        A multicenter trial of doxazosin in West Germany.
        Am J Cardiol. 1987; 59: 40G-45G
        • Alabaster VA
        • Davey MJ
        The alpha1-adrenoceptor antagonist profile of doxazosin: Preclinical pharmacology.
        Br J Clin Pharmacol. 1986; 21 (Suppl 1): 9S-17S
        • Elliott HL
        • Meredith PA
        • Vincent J
        • Reid JL
        Clinical pharmacological studies with doxazosin.
        Br J Clin Pharmacol. 1986; 21 (Suppl 1): 27S-31S
        • Poll JL
        Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension.
        Am J Cardiol. 1987; 59: 46G-50G
        • Todd PA
        • Heel RC
        Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.
        Drugs. 1986; 31: 198-248
        • Collins R
        • Peto R
        • MacMahon S
        • et al.
        Blood pressure, stroke and coronary heart disease.
        Lancet. 1990; 335 (Part 2, short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context): 827-838
        • Moan A
        • Os I
        • Hjermann I
        • Kjeldsen SE
        Hypertension therapy and risk of coronary artery disease: How do antihypertensives affect metabolic factors?.
        Cardiology. 1995; 86: 89-93
        • Rabkin SW
        • Huff MW
        • Newman C
        • et al.
        Lipids and lipoproteins during antihypertensive drug therapy. Comparison of doxazosin and atenolol in a randomized, double-blind trial: The Alpha Beta Canada Study.
        Hypertension. 1994; 24: 241-248
        • Lund-Johanson P
        • Omvik P
        • Haugland H
        Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
        Br J Clin Pharmacol. 1986; 21 (Suppl 1): 45S-54S
        • Talseth T
        • Westlie L
        • Daae L
        Doxazosin and atenolol as monotherapy in mild and moderate hypertension: A randomized, parallel study with a three-year follow-up.
        Am Heart J. 1991; 121: 280-285
        • Trost BN
        • Weidmann P
        • Riesen W
        • et al.
        Comparative effects of doxazosin and hydrochlorothiazide on serum lipids and blood pressure in essential hypertension.
        Am J Cardiol. 1987; 59: 99G-104G
        • Torvik D
        • Madsbu HP
        An open one-year comparison of doxazosin and prazosin for mild to moderate essential hypertension.
        Am J Cardiol. 1987; 59: 68G-72G
        • Carruthers G
        • Dessain P
        • Fodor G
        Comparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertension.
        Am J Cardiol. 1993; 71 (The Alpha Beta Canada (ABC) Trial Group): 575-581
        • Wilson PWF
        • Castelli WP
        • Kannel WB
        Coronary risk prediction in adults (The Framingham Heart Study).
        Am J Cardiol. 1987; 59: 91G-94G